Axovant Sciences Ltd (AXON) Expected to Post Earnings of -$0.38 Per Share

Brokerages expect Axovant Sciences Ltd (NASDAQ:AXON) to report earnings of ($0.38) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Axovant Sciences’ earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.52). Axovant Sciences posted earnings of ($0.64) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 40.6%. The firm is scheduled to report its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Axovant Sciences will report full-year earnings of ($1.67) per share for the current year, with EPS estimates ranging from ($2.22) to ($0.78). For the next fiscal year, analysts forecast that the company will post earnings of ($1.35) per share, with EPS estimates ranging from ($2.56) to ($0.73). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Axovant Sciences.

Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.33).



Several analysts have commented on the company. BidaskClub cut Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 12th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Thursday, July 12th. Cowen restated a “hold” rating on shares of Axovant Sciences in a report on Thursday, September 20th. Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a report on Monday, July 9th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Axovant Sciences in a report on Monday, August 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. Axovant Sciences has a consensus rating of “Hold” and a consensus target price of $4.85.

Axovant Sciences stock opened at $2.37 on Tuesday. The stock has a market cap of $295.44 million, a P/E ratio of -1.15 and a beta of -0.01. Axovant Sciences has a 52 week low of $1.02 and a 52 week high of $6.59. The company has a debt-to-equity ratio of 1.48, a current ratio of 2.34 and a quick ratio of 2.34.

In other Axovant Sciences news, Director George Bickerstaff purchased 25,000 shares of the stock in a transaction on Thursday, August 9th. The stock was bought at an average price of $2.07 per share, for a total transaction of $51,750.00. Following the acquisition, the director now directly owns 50,000 shares of the company’s stock, valued at $103,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Axovant Sciences by 3.4% in the 1st quarter. BlackRock Inc. now owns 3,012,515 shares of the biotechnology company’s stock valued at $4,006,000 after purchasing an additional 100,296 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Axovant Sciences by 175.6% in the 1st quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock valued at $1,770,000 after purchasing an additional 847,946 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Axovant Sciences by 183.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,450 shares of the biotechnology company’s stock valued at $1,120,000 after purchasing an additional 320,450 shares in the last quarter. A.R.T. Advisors LLC lifted its stake in shares of Axovant Sciences by 148.9% in the 1st quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 249,074 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Axovant Sciences by 2,519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 176,227 shares in the last quarter. 9.38% of the stock is currently owned by institutional investors and hedge funds.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Story: What is the float in trading stocks?

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply